Literature DB >> 11152345

Genotype-phenotype correlation in gemistocytic astrocytomas.

S Kösel1, B W Scheithauer, M B Graeber.   

Abstract

OBJECTIVE: Gemistocytic astrocytomas often behave aggressively and carry the least favorable prognosis among diffuse astrocytomas. The frequency of p53 mutations has been reported to be significantly higher in the gemistocytic variant as compared with other astrocytomas.
METHODS: Between 1985 and 1998, we selected 25 tumor samples from among 201 samples from patients with gemistocytic astrocytomas operated on at the Mayo Clinic. Exons 5 to 8 of the p53 gene were sequenced using an automated deoxyribonucleic acid sequencer. Morphometric characterization of individual gemistocytes was performed using an image analysis program.
RESULTS: Of 25 tissue samples analyzed, 16 were found to carry a p53 missense mutation (three in exon 5, three in exon 6, one in exon 7, and nine in exon 8), and one sequence variant was synonymous. Mutations were clustered at codons 151 (2 of 17 mutations), 193 (3 of 17 mutations), and 273 (5 of 17 mutations) of the p53 gene. Patients whose tumors carried a p53 mutation were significantly younger than other patients, and their tumors tended to accumulate more p53 protein than those of other patients. Phenotype analysis of gemistocytes revealed that the sizes of tumor cell nuclei and of entire tumor cells in the same tissue area were positively correlated. Smaller tumor cell nuclei tended to be less circular or more atypical. In addition, more atypical gemistocytes were found in tumors lacking a wild-type p53 allele as well as in tissue from patients whose postoperative survival was shorter.
CONCLUSION: Our data confirm that the frequency of p53 mutations is significantly higher (approximately twofold) in gemistocytic astrocytomas as compared with other astrocytoma subtypes. Whether the high frequency of p53 mutations contributes to the more aggressive behavior of gemistocytic astrocytomas, however, remains unclear.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152345     DOI: 10.1097/00006123-200101000-00033

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Gemistocytes in astrocytomas: are they a significant prognostic factor?

Authors:  Dely C Martins; Suzana M Malheiros; Lucila H Santiago; João N Stávale
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

Review 2.  Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective.

Authors:  Tarik Tihan; Poonam Vohra; Mitchel S Berger; G Evren Keles
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database.

Authors:  Lyubov E Salnikova
Journal:  Neuromolecular Med       Date:  2014-01-31       Impact factor: 3.843

4.  Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations--a study of 32 cases.

Authors:  Singh Avninder; Mehar Chand Sharma; Prabal Deb; Veer Singh Mehta; Asish Kumar Karak; Ashok Kumar Mahapatra; Chitra Sarkar
Journal:  J Neurooncol       Date:  2006-04-14       Impact factor: 4.130

5.  TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.

Authors:  Emeline Gillet; Agusti Alentorn; Brahima Doukouré; Emeline Mundwiller; Hinke F van Thuijl; Hinke van Thuij; Jaap C Reijneveld; José Alfonso Meza Medina; Amélie Liou; Yannick Marie; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  J Neurooncol       Date:  2014-03-04       Impact factor: 4.130

6.  The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.

Authors:  Matthew D Cykowski; Richard A Allen; Angela C Kanaly; Kar-Ming Fung; Roxanne Marshall; Arie Perry; Ethan D Stolzenberg; S Terence Dunn
Journal:  J Neurooncol       Date:  2013-09-21       Impact factor: 4.506

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.